Skip to content
The Kids Research Institute Australia logo
Donate

Search

Immunogenicity and Immune Memory after a Pneumococcal Polysaccharide Vaccine Booster in a High-Risk Population Primed with Pneumococcal Conjugate Vaccine

PPV is immunogenic in 9-month-old children at high risk of pneumococcal infections and does not affect the capacity to produce protective immune responses

Australian Aboriginal children with otitis media have reduced antibody titers to specific nontypeable Haemophilus influenzae vaccine antigens

decreased serum IgG responses to NTHi outer membrane proteins may contribute to the development of chronic and severe OM in Australian Aboriginal children

Bacterial Respiratory Infectious Disease Group (BRIDG)

The Bacterial Respiratory Infectious Disease Group (BRIDG) has a major focus ear and lung disease involving Streptococcus pneumoniae and Haemophilus influenzae.

Associate Professor Lea-Ann Kirkham

Co-Head, Bacterial Respiratory Infectious Disease Group; Microbiology Lead, Wesfarmers Centre of Vaccines & Infectious Diseases

Clinical predictors of hypoxic pneumonia in children from the Eastern Highlands Province, Papua New Guinea: secondary analysis of two prospective observational studies

Pneumonia is the leading cause of death in young children globally and is prevalent in the Papua New Guinea highlands. We investigated clinical predictors of hypoxic pneumonia to inform local treatment guidelines in this resource-limited setting.

An infant mouse model of influenza-driven nontypeable Haemophilus influenzae colonization and acute otitis media suitable for preclinical testing of novel therapies

Nontypeable Haemophilus influenzae (NTHi) is a major otitis media (OM) pathogen, with colonization a prerequisite for disease development. Most acute OM is in children <5 years old, with recurrent and chronic OM impacting hearing and learning. Therapies to prevent NTHi colonization and/or disease are needed, especially for young children. Respiratory viruses are implicated in driving the development of bacterial OM in children.

Defining the cellular immune response to vaccines for enhanced protection from invasive pneumococcal disease

Peter Lea-Ann Ruth Richmond Kirkham Thornton MBBS MRCP(UK) FRACP PhD PhD Head, Vaccine Trials Group Co-Head, Bacterial Respiratory Infectious Disease

Development of molecular tools for accurate diagnosis and disease surveillance (including vaccine impact)

Janessa Lea-Ann Peter Ruth Pickering Kirkham Richmond Thornton BSc PhD PhD MBBS MRCP(UK) FRACP PhD Senior Research Fellow (currently HOT NORTH Early

Does mum know best? Should we be vaccinating mothers to protect their babies from ear and lung disease?

Elke Lea-Ann Ruth Peter Seppanen Kirkham Thornton Richmond BSc PhD PhD PhD MBBS MRCP(UK) FRACP Program Manager, Bacterial Respiratory Infectious